Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Net sales increased, mainly due to rush demand arising from supply concerns against the backdrop of worsening conditions in the Middle East. Operating profit decreased despite the effects of some price revisions, owing to higher raw material prices and increased selling, general and administrative expenses associated with promotional activities in the Medical business.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥12,264 million (YoY +2.9%) |
| Operating profit | ¥621 million (YoY -4.7%) |
| Ordinary income | ¥668 million (YoY -1.2%) |
| Profit attributable to owners of the parent | ¥393 million (YoY +0.1%) |
| Net income per share | ¥19.49 |
| Equity ratio | End of the current fiscal period 67.1 / End of previous period 65.9 |
| Total assets | ¥65,486 million |
| Net assets | ¥43,948 million |
| Full-year earnings forecast | Net Sales ¥52,000 million (YoY +3.0%) / Operating profit ¥3,600 million (YoY +58.5%) / Ordinary income ¥3,700 million (YoY +51.5%) / Net income ¥2,300 million (YoY +39.2%) |
| Annual Dividend Forecast | ¥40 → ¥40（0.0%） |
| Segment revenue | Medical Business ¥6,006 million (YoY +1.4%) / Tape business ¥6,257 million (YoY +4.3%) |
| Segment profit | Medical Business ¥1,402 million (YoY -9.9%) / Tape business ¥411 million (YoY +64.9%) |
| Regional sales | Domestic ¥11,052 million / Overseas expansion ¥1,211 million |
| Depreciation and amortization | ¥664 million |
| Impairment loss | No applicable matters |
| Breakdown of extraordinary income (loss) | Extraordinary income No applicable matters / Extraordinary loss Factory reorganization costs ¥37 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies (no company names provided) / Excluded 0 companies (no company names provided) |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 20,738,006 Shares |
| Treasury Shares at Period-End | 557,097 Shares |
| Factors Behind Changes in Business Performance | Net sales increased, mainly due to rush demand arising from supply concerns against the backdrop of worsening conditions in the Middle East. Operating profit decreased despite the effects of some price revisions, owing to higher raw material prices and increased selling, general and administrative expenses associated with promotional activities in the Medical business. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales increased, mainly due to rush demand arising from supply concerns against the backdrop of worsening conditions in the Middle East. Operating profit decreased despite the effects of some price revisions, owing to higher raw material prices and increased selling, general and administrative expenses associated with promotional activities in the Medical business.